ABSTRACT
The selective serotonin-reuptake inhibitors (SSRIs) are now the drugs of choice for the treatment of juvenile depression (Emslie et al., 1998). Together with fluoxetine, other SSRIs currently prescribed for children and adolescents with mood disorders, sertraline (Zoloft), paroxetine (Paxil), fluvoxamine (Luvox) and citalopram (Celexa), are discussed in detail in Chapter 9 of this textbook. Novel antidepressants [not chemically related to the tricyclics (TCAs) or the SSRIs] such as bupropion (Wellbutrin), trazodone (Desyrel), nefazodone (Serzone), mirtazapine (Remeron), and venlafaxine (Effexor) have been prescribed to children and adolescents for unlabeled (non-FDA-approved) indications. Their psychopharmacological profile and relevant pediatric studies are summarized in this chapter. Together with these agents, we will also discuss the adjuvant treatment of depression with thyroid hormones.
